Peter A. Spiegler

IMPACTS ON MANAGEMENT OF HIGH-RISK LUNG NODULES AND PATIENT OUTCOMES AFTER VIRTUAL REVIEW BY A MULTIDISCIPLINARY LUNG NODULE REVIEW BOARD

Keshav Mangalick, HUGH J REMAR, RACHEL NELSON, MARIA BANVARD et autres

Low dose vs high dose tocilizumab in COVID-19 patients with hypoxemic respiratory failure

Juri Chung, Shari B. Brosnahan, Shahidul Islam, Diana Altshuler et autres

PURPOSE: Tocilizumab has been shown to decrease mortality when used concomitantly with steroids in COVID-19 with 8 mg/kg (max 800 mg) being the standard dose. Our study sought to assess whether a low dose (400 mg) shows similar benefit compared to a …

us (code pays fourni par la source)

A 33-Year-Old Man With Acute Hemoptysis

Erin Meier, Douglas S. Katz, Peter A. Spiegler

us (code pays fourni par la source)

1108: LOW-DOSE VERSUS HIGH-DOSE TOCILIZUMAB IN COVID-19 PATIENTS WITH HYPOXIC RESPIRATORY FAILURE

Wai Man Wang, Xian Jie Chen, Juri Chung, Wai Kin Li et autres

Introduction: Tocilizumab has been shown to decrease mortality when used concomitantly with steroids in COVID-19. Tocilizumab dose of 8 mg/kg (max: 800 mg), stemmed from the RECOVERY trial, has been the standard dose for COVID. Due to a drug shortage of tocilizumab, …

us (code pays fourni par la source)

The incidence of propofol infusion syndrome in critically-ill patients

Wai Kin Li, Xian Jie Cindy Chen, Diana Altshuler, Shahidul Islam et autres

us (code pays fourni par la source)

A Randomized Double-Blinded Placebo Controlled Trial of Clazakizumab for the Treatment of COVID-19 Pneumonia With Hyperinflammation*

Bonnie E. Lonze, Peter A. Spiegler, Russell Wesson, Nada Alachkar et autres

OBJECTIVES: We designed this study to test whether clazakizumab, a direct interleukin-6 inhibitor, benefits patients hospitalized with severe or critical COVID-19 disease accompanied by hyperinflammation. DESIGN: Multicenter, randomized, double-blinded, placebo-controlled, seamless phase II/III trial. SETTING: Five U.S. medical centers. PATIENTS: Adults inpatients …

us (code pays fourni par la source)

Pulmonary rehabilitation

Mangalore Amith Shenoy, Peter A. Spiegler

Pulmonary rehabilitation (PR) is a ‘comprehensive intervention based on a thorough patient assessment followed by patient-tailored therapies that include exercise training, education, and behavior change, designed to improve the physical and psychological condition of people with chronic respiratory disease and to promote …

us (code pays fourni par la source)

Idiopathic pulmonary fibrosis: Current and future treatment

Daniel S. Glass, David J. Grossfeld, Heather A. Renna, Priya Agarwala et autres

OBJECTIVES: Idiopathic pulmonary fibrosis (IPF) is a chronic fibrotic lung disease characterized by dry cough, fatigue, and progressive exertional dyspnea. Lung parenchyma and architecture is destroyed, compliance is lost, and gas exchange is compromised in this debilitating condition that leads inexorably to …

us (code pays fourni par la source)

925: PREVALENCE OF PROPOFOL INFUSION SYNDROME IN CRITICALLY ILL PATIENTS

Wai Kin Li, Xian Jie Chen, Diana Altshuler, Shahidul Islam et autres

Li, Wai Kin1; Chen, Xian Jie2; Altshuler, Diana3; Islam, Shahidul4; Emerson, Liane5; Spiegler, Peter2; Bender, Michael6 Author Information

us (code pays fourni par la source)

Reply: Low-Dose Tocilizumab With High-Dose Corticosteroids in Patients Hospitalized for COVID-19 Hypoxic Respiratory Failure Improves Mortality Without Increased Infection Risk

Xian Jie Cindy Chen, Diana Altshuler, Peter A. Spiegler, Shari B. Brosnahan

us (code pays fourni par la source)

Low-Dose Tocilizumab With High-Dose Corticosteroids in Patients Hospitalized for COVID-19 Hypoxic Respiratory Failure Improves Mortality Without Increased Infection Risk

Shari B. Brosnahan, Xian Jie Cindy Chen, Juri Chung, Diana Altshuler et autres

Background Severe hypoxic respiratory failure from COVID-19 pneumonia carries a high mortality risk. There is uncertainty surrounding which patients benefit from corticosteroids in combination with tocilizumab and the dosage and timing of these agents. The balance of controlling inflammation without increasing the …

us (code pays fourni par la source)

Idiopathic pulmonary fibrosis: Molecular mechanisms and potential treatment approaches

Daniel S. Glass, David J. Grossfeld, Heather A. Renna, Priya Agarwala et autres

us (code pays fourni par la source)